Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Angela Mc Rose*, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer HowardFrancisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem Binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia Cjl Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O'Donnell, Indrė Jonikaitė, Regina Demlová, I-MOVE-COVID-19 hospital study team

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

Original languageEnglish
Article number2300186
Number of pages16
Issue number47
Publication statusPublished - Nov 2023


  • Humans
  • Adult
  • COVID-19/epidemiology
  • BNT162 Vaccine
  • RNA, Viral
  • SARS-CoV-2
  • Vaccine Efficacy
  • Hospitalization
  • Europe/epidemiology


Dive into the research topics of 'Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021'. Together they form a unique fingerprint.

Cite this